We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+15.83%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$434M
AUM Growth
+$154M
(+55%)
Cap. Flow
+$130M
Cap. Flow
% of AUM
30.03%
Top 10 Holdings %
Top 10 Hldgs %
39.11%
Holding
88
New
19
Increased
48
Reduced
6
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$23.2M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$8.04M |
| 3 |
AbbVie
ABBV
|
+$6.82M |
| 4 |
ITMN
INTERMUNE INC
ITMN
|
+$6.35M |
| 5 |
AGN
Allergan plc
AGN
|
+$6.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$9.8M |
| 2 |
GENT
GENTIUM SPA ADS
GENT
|
+$6.82M |
| 3 |
AET
Aetna Inc
AET
|
+$4.27M |
| 4 |
Puma Biotechnology
PBYI
|
+$3.26M |
| 5 |
Edwards Lifesciences
EW
|
+$2.79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.37% |
| 2 | Industrials | 1.53% |
| 3 | Technology | 0.49% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Acadia Pharmaceuticals
ACAD
$5.03B
| – | – |
-31,418
| Closed | -$785K |
|
77
Cencora
COR
$61.2B
| – | – |
-22,500
| Closed | -$1.58M |
|
|
78
Edwards Lifesciences
EW
$51.7B
| – | – |
-255,000
| Closed | -$2.79M |
|
79
Nektar Therapeutics
NKTR
$2.58B
| – | – |
-4,333
| Closed | -$738K |
|
|
ISEE
80
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-19,800
| Closed | -$641K |
|
|
AET
81
DELISTED
Aetna Inc
AET
| – | – |
-62,300
| Closed | -$4.27M |
|
|
AEGR
82
DELISTED
Aegerion Pharmaceuticals
AEGR
| – | – |
-39,250
| Closed | -$2.79M |
|
|
XNPT
83
DELISTED
XENOPORT, INC.
XNPT
| – | – |
-175,000
| Closed | -$1.01M |
|
|
TRNX
84
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| – | – |
-130,000
| Closed | -$2.44M |
|
|
AUXL
85
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| – | – |
-100,000
| Closed | -$2.07M |
|
|
CADX
86
DELISTED
CADENCE PHARMACEUTICALS, INC COM STK
CADX
| – | – |
-89,500
| Closed | -$810K |
|
|
GENT
87
DELISTED
GENTIUM SPA ADS
GENT
| – | – |
-119,500
| Closed | -$6.82M |
|
|
AIRM
88
DELISTED
Air Methods Corp
AIRM
| – | – |
-17,000
| Closed | -$992K |
|
Similar funds
ACM
BCM
PP
GAM
FACM
RMC
JIP
II
Rock Springs Capital Management's Q1 2014 Portfolio in Review
As of Q1 2014, Rock Springs Capital Management held 88 positions worth $434M, up 55% from $280M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Rock Springs Capital Management deployed $130M of net new capital in Q1 2014, opening 19 new positions and adding to 48 existing holdings. Its largest new stake was Johnson & Johnson: 250,000 shares worth $24.6M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 73% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was State Street Health Care Select Sector SPDR ETF, an estimated $9.8M trimmed.
- Rock Springs Capital Management's largest Q1 2014 buy was Johnson & Johnson: 250,000 shares worth $24.6M.
- Rock Springs Capital Management added most to AbbVie in Q1 2014, an estimated $6.82M increase.
- Rock Springs Capital Management's biggest Q1 2014 reduction was State Street Health Care Select Sector SPDR ETF, cutting an estimated $9.8M.
- Rock Springs Capital Management fully exited GENTIUM SPA ADS in Q1 2014, selling an estimated $6.82M.
- Rock Springs Capital Management's ten largest holdings make up 39% of its $434M portfolio in Q1 2014.
- Rock Springs Capital Management opened 19 new positions and closed 13 in Q1 2014.
- Rock Springs Capital Management's portfolio value rose 55% quarter-over-quarter to $434M.
Based on Rock Springs Capital Management's 13F filing for Q1 2014, filed 15 May 2014.